Carlsmed Raises Series C to Support aprevo

Carlsmed announced a $52.5 million Series C funding round co-led by B Capital and U.S. Venture Partners. Proceeds support accelerated commercialization of the aprevo personalized spine surgery platform for lumbar fusion procedures and the development of aprevo for cervical fusions, which will launch in 2025.

Carlsmed received Breakthrough...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us